Press releases

Dicot reports positive results from study with the drug candidate Libiguin® for the treatment of sexual dysfunctions

Uppsala, September 14, 2020. Dicot today announces the first results of the animal study conducted together with Pelvipharm.  The results show that Dicot's drug candidate Libiguin® had a significant and dose-dependent effect on erection compared to placebo at all measured parameters in Pelvipharm's established animal model. Next steps include further data reviewing with Pelvipharm to optimize the next study in the best way. Pelvipharm SAS is a world-leading preclinical contract laboratory (CRO) specializing in the evaluation of sexual dysfunction in animal models and more studies with Libiguin® are planned.

Dicot develops the drug candidate Libiguin® to treat sexual dysfunctions such as erectile dysfunction and premature ejaculation. Libiguin® has its origins in the research conducted at Uppsala University by Professor Jarl Wikberg to treat sexual disability.  Previous animal trials and the traditional folk medicine use from Madagascar demonstrate the potential for Libiguin® as treatment of erection problems and premature ejaculation. Positive results from the new preclinical study together with Pelvipharm provide a solid basis for further preclinical testing in erectile dysfunction, although much development work remains before the clinical phase.

A preclinical development program including safety evaluation of Libiguin® is ongoing, based on raw material from nature and verified manufacturing processes. Dicot has previously announced that it has entered a research collaboration with Pelvipharm, a world-leading contract laboratory based in France. The purpose of the research collaboration is to identify the mechanism of action of Libiguin®, which is a crucial step regarding the future area of use.

"Our long-term goal is for Libiguin® to be the first choice in the treatment of erection problems and premature ejaculation. The results from this study are very encouraging for us and really indicate that Libiguin® have the potential of becoming a new drug for the treatment of sexual dysfunctions in the future", says Göran Beijer, CEO of Dicot AB.

"We are happy to share our insights into this exciting data review and are confident in pursuing this research with Dicot", says Delphine Behr-Roussel, CEO of Pelvipharm SAS.

For further information, please contact:

Göran Beijer, CEO
Tel: +46 70-663 60 09
Email: goran.beijer@dicot.se

About Dicot AB

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead drug candidate, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 1,600 shareholders. For more information see www.dicot.se.

About Pelvipharm SAS

Pelvipharm is a worldwide leading preclinical CRO delivering preclinical research services in urology and urogenital disorders (Benign Prostatic Hyperplasia, Overactive Bladder, Spinal Cord Injury, Painful bladder syndrome/Interstitial cystitis), male sexual dysfunctions (Erectile Dysfunction, Premature Ejaculation), women's health (Vaginal Atrophy, Menopause-related Dysfunctions, Female Sexual Dysfunction) and urogenital complications of cardiovascular / metabolism medicine and eating disorders (Hypertension, Atherosclerosis, Metabolic Syndrome, Diabetes) using a unique platform of both in vivo experimental models and in vitro animal and human tissue-based specific assays.

This information is such that Dicot AB is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on September 14, 2020.

Contact us

Dicot AB
Dag Hammarskjölds Väg 30
SE-752 37 Uppsala SWEDEN
+46 (0) 70-663 60 09
info@dicot.se

The information is processed according to our privacy policy.